LONDON, 26 – Argenta, the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) specialised in animal health, announced today the appointment of Mark Bridgewater in the newly created position of Chief Business and Growth Officer, effective immediately.
Mark will be a member of Argenta’s Executive Leadership Team and is responsible for growing and advancing Argenta’s commercial strategy. Mark will build a centralized commercial customer-centric organization that focuses on business development across the entire global organization. He will work closely with Phil Huse, Chief Commercial Officer, and Annemieke de Keijzer, Global Head of Communications & Marketing.
Will Downie, CEO of Argenta said: “Mark’s years of global commercial experience in enterprise business development and marketing make him the ideal person to advance Argenta’s growth and development. I am excited to work with Mark to further improve our end-to-end business development, marketing, and go-to-market strategy.”
Prior to joining Argenta, Mark was the Chief Commercial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. Prior to working with Vectura, Mark held senior positions in business development at Flex Health Solutions and Catalent.
Mark Bridgewater said: “I am thrilled to be joining the company at this exciting time and with Argenta’s partners front of mind, eager to work alongside a talented team to help enhance and accelerate its ‘Molecule to Market’ strategy and overall business growth.”
Founded in New Zealand, Argenta’s talented and committed employees are dedicated to delivering excellence in animal health to customers around the world. With research and/or GMP manufacturing operations in Germany, New Zealand, Spain, the United Kingdom, and the United States, Argenta holds a unique position as the only combined global contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) specialising in animal health.
Argenta operates from Molecule to Market in partnership with customers of all sizes from all corners of the world, supporting their research and development, clinical research, regulatory, scale-up and manufacturing needs along the veterinary product development journey.
The day-to-day ethos that drives Argenta forward is a mission focused on global partnerships, a Molecule to Market approach, and innovation. At the core of the business and the organisation is collaboration – among the global employee base and with their customers.
For more information, please visit www.argentaglobal.com.
Annemieke de Keijzer